@article{5ec49b4e806141abbf23a3ad7478d719,
title = "Exploring the manifestations of anxiety in children with autism spectrum disorders",
abstract = "This study explores the manifestation and measurement of anxiety symptoms in 415 children with ASDs on a 20-item, parent-rated, DSM-IV referenced anxiety scale. In both high and low-functioning children (IQ above vs. below 70), commonly endorsed items assessed restlessness, tension and sleep difficulties. Items requiring verbal expression of worry by the child were rarely endorsed. Higher anxiety was associated with functional language, IQ above 70 and higher scores on several other behavioral measures. Four underlying factors emerged: Generalized Anxiety, Separation Anxiety, Social Anxiety and Over-arousal. Our findings extend our understanding of anxiety across IQ in ASD and provide guidance for improving anxiety outcome measurement.",
keywords = "Anxiety, Autism spectrum disorders, Clinical Trials, Measurement",
author = "Victoria Hallett and Luc Lecavalier and Sukhodolsky, {Denis G.} and Noreen Cipriano and Aman, {Michael G.} and McCracken, {James T.} and McDougle, {Christopher J.} and Elaine Tierney and King, {Bryan H.} and Eric Hollander and Linmarie Sikich and Joel Bregman and Evdokia Anagnostou and Craig Donnelly and Lily Katsovich and Kimberly Dukes and Benedetto Vitiello and Kenneth Gadow and Lawrence Scahill",
note = "Funding Information: Conflict of interest Dr. Scahill: Roche, consultant; Pfizer, consultant; Bracket, consultatnt, BioMarin, consultant. Shire, research support; Roche, research support; Pfizer, research support. Dr. Aman: Roche, consultant; Bristol-Meyers Squibb, consultant, research grant; Forest, consultant; Pfizer, consultant; Supernus, consultant; Johnson & Johnson, research grant. Dr. Gadow: Checkmate Plus, publisher of the Child and Adolescent Symptom Invetory-4; Dr. McDougle: Bristol-Myers Squibb, research grant, speaker{\textquoteright}s bureau. Dr. McCracken: salary from UCLA, research support from NIH, Seaside Therapeutics, Roche, and Otsuka; consultant income from Novartis, BioMarin, PharmaNet, and Noven; speaker{\textquoteright}s honoraria from the Tourette Syndrome Association; and research study drug supply from Shire; Dr. Arnold: AstraZeneca, advisory board; Biomarin, advisory board; CureMark, research funding; Lilly, research funding; Noven, advisory board; Seaside therapeutics, advisory board; Shire, research funding. Dr. Tierney: BioMarin, consultant. Dr. Donnelly: consultant for Eli Lilly Pharmaceutical Company, Abbott Pharmaceutical Company and Shire Pharmaceuticals. He has served on the Speaker{\textquoteright}s Bureau for Eli Lilly, and Shire. He has received research funding from Eli Lilly. Dr. Hollander reports serving as a consultant to Neuropharm. Dr. King reports serving as a consultant to Biomarin and Neuropharm and as an unpaid consultant to Forest, Nastech, and Seaside Therapeutics. He has received or has pending research grant support from Neuropharm and Seaside Therapeutics. Dr. Sikich has received support from Bristol Myers Squibb and Pfizer, participated in clinical trials sponsored by Neuropharm, Curemark, Seaside Pharmaceuticals, and recieved medications or software Janssen Pharmaceutica, Eli Lilly, Pfizer, Bristol Myers Squibb and Posit-science. Dr. Hallett, Dr. Lecavalier, Dr. Sukhodolsky, Dr. Vitiello, Ms Katsovich Dr. Anagnostou, Dr. Bregman, and Dr. Dukes report no financial relationships with commercial interests. Funding Information: Acknowledgments The authors acknowledge Ann Wagner, PhD and Louise Ritz, MBA at NIMH; James Robinson, MED, at NKI; Mark Davies, MPH at NY State Psychiatric Institute, Stacey Grinnon, MA at KAI Research, Inc; Deborah Hirtz MD at the National Institute of Neurological Disorders and Stroke, Bethesda, Lisa Sullivan, PhD at Boston University; Fay Robinson, MPH at DMSTAT and James Dziura, PhD, Sunkyung Yu, MS, Yanhong Deng, MPH and Allison Gavaletz, BS at Yale University. The RUPP studies were funded by the following NIMH grants and contracts: N01MH70009 and U10MH66764 (Yale); N01MH70001 and U10MH66766 (Indiana University); N01MH80011 and U10MH66768 (Ohio State University); N01MH70010 (UCLA). This publication was also supported by the Yale Clinical and Translational Science Award (CTSA) UL1RR024139, Indiana University CTSA UL1 RR025761, and Ohio State University CTSA UL1 RR025755 from the National Center for Research Resources (NCRR). The STAART citalopram study was funded by NIH via the following center contracts: Mount Sinai School of Medicine: U54-MH066673; University of North Carolina at ChapelHill: U54-MH066418; University of California at Los Angeles: U54-MH068172; Yale University: U54-MH066494. Dartmouth Medical School and Boston University: U54-MH066398; and DM-STAT, Inc, Boston: U01-HD045023.",
year = "2013",
month = oct,
doi = "10.1007/s10803-013-1775-1",
language = "English (US)",
volume = "43",
pages = "2341--2352",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "10",
}